Citi lowered the firm’s price target on Sight Sciences (SGHT) to $4.60 from $5.80 and keeps a Neutral rating on the shares as part of a 2025 outlook for the U.S. medical technology sector. The stocks that outperformed in 2024 followed the traditional med tech path, and Citi expects the same in 2025: launching differentiated products that can be leveraged to the bottom-line, with management teams providing consistent delivery, the analyst tells investors in a research note. Citi names Boston Scientific (BSX) and Insulet (PODD) its top picks for 2025.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences initiated with a Buy at UBS
- Sight Sciences assumed with an Equal Weight at Morgan Stanley
- Sight Sciences price target lowered to $5 from $7 at Morgan Stanley
- Sight Sciences price target lowered to $5.50 from $6 at Piper Sandler
- Sight Sciences Reports Modest Growth and Optimistic Outlook